{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:38:19Z","timestamp":1792643899664,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-026-02774-6","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:42:45Z","timestamp":1786959765000},"page":"1933-1947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expression profiles of selected circulating microRNAs (miR-192-5p and miR-155-3p) in NAFLD and their association with obesity and type 2 diabetes mellitus"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7638-6595","authenticated-orcid":false,"given":"Rana","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Sadaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"El-Zayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar H.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Awadein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla O.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2774_CR1","doi-asserted-by":"crossref","unstructured":"Teng MLP, Ng CH, Huang DQ, Chan KE, Tan DJH, Lim WH et al (2022) Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol [Internet]. [cited 2025 Aug 9];29(Suppl):S32. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10029957\/","DOI":"10.3350\/cmh.2022.0365"},{"key":"2774_CR2","doi-asserted-by":"publisher","unstructured":"Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W et al Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord [Internet]. 2022 Dec 1 [cited 2025 Aug 9];22(1):1\u20139. Available from: https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12902-022-00980-1","DOI":"10.1186\/s12902-022-00980-1"},{"issue":"4","key":"2774_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.53469\/jcmp.2025.07(04).16","volume":"7","author":"C Zhu","year":"2025","unstructured":"Zhu C, Deng Z (2025) Research Advances in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. J Contemp Med Pract 7(4):82\u201385","journal-title":"J Contemp Med Pract"},{"key":"2774_CR4","doi-asserted-by":"crossref","unstructured":"Ziamanesh F, Mohammadi M, Ebrahimpour S, Tabatabaei-Malazy O, Mosallanejad A, Larijani B Unraveling the link between insulin resistance and Non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): A Narrative Review. J Diabetes Metab Disord [Internet]. 2023 Dec 1 [cited 2025 Aug 9];22(2):1083. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10638269\/","DOI":"10.1007\/s40200-023-01293-3"},{"key":"2774_CR5","doi-asserted-by":"crossref","unstructured":"Jin X, Qiu T, Li L, Yu R, Chen X, Li C et al Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B [Internet]. 2023 Jun 1 [cited 2025 Aug 9];13(6):2403\u201324. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2211383523000126","DOI":"10.1016\/j.apsb.2023.01.012"},{"key":"2774_CR6","doi-asserted-by":"publisher","unstructured":"Lauria F, Venezia A, Iacomino G Circulating MicroRNA (miRNA)s as Biological Markers and Links with Obesity and Obesity-Related Morbid Conditions. 2022 [cited 2025 Aug 9];495\u2013516. Available from: https:\/\/link.springer.com\/rwe\/https:\/\/doi.org\/10.1007\/978-3-031-07389-2_29","DOI":"10.1007\/978-3-031-07389-2_29"},{"key":"2774_CR7","doi-asserted-by":"crossref","unstructured":"Nunes S, Bastos R, Marinho AI, Vieira R, Ben\u00edcio I, de Noronha MA et al (2025) Recent advances in the development and clinical application of miRNAs in infectious diseases. Non-coding RNA Res [Internet]. Feb 1 [cited 2025 Aug 9];10:41\u201354. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2468054024001380","DOI":"10.1016\/j.ncrna.2024.09.005"},{"key":"2774_CR8","doi-asserted-by":"crossref","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne) [Internet]. 2018 Aug 3 [cited 2025 Aug 9];9(AUG):402. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6085463\/","DOI":"10.3389\/fendo.2018.00402"},{"key":"2774_CR9","doi-asserted-by":"crossref","unstructured":"Niazi SK, Magoola M (2024) MicroRNA Nobel Prize: Timely Recognition and High Anticipation of Future Products\u2014A Prospective Analysis. Int J Mol Sci. Vol 25, Page 12883 [Internet]. 2024 Nov 29 [cited 2025 Aug 9];25(23):12883. Available from: https:\/\/www.mdpi.com\/1422-0067\/25\/23\/12883\/htm","DOI":"10.3390\/ijms252312883"},{"key":"2774_CR10","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Pastor AR, Infante-Men\u00e9ndez J, Escribano \u00d3, G\u00f3mez-Hern\u00e1ndez A (2020) miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease. Front Med [Internet]. Sep 22 [cited 2025 Aug 9];7:527059. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7546803\/","DOI":"10.3389\/fmed.2020.527059"},{"key":"2774_CR11","doi-asserted-by":"crossref","unstructured":"Rahdan F, Saberi A, Saraygord-Afshari N, Hadizadeh M, Fayeghi T, Ghanbari E et al (2024) Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights. Heliyon [Internet]. Oct 30 [cited 2025 Oct 9];10(20):e39489. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S240584402415520X","DOI":"10.1016\/j.heliyon.2024.e39489"},{"key":"2774_CR12","doi-asserted-by":"crossref","unstructured":"Mahesh G, Biswas R MicroRNA-155: A Master Regulator of Inflammation. J Interferon Cytokine Res [Internet]. 2019 Jun 1 [cited 2025 Oct 9];39(6):321\u201330. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30998423\/","DOI":"10.1089\/jir.2018.0155"},{"key":"2774_CR13","doi-asserted-by":"crossref","unstructured":"Dawson O, Piccinini AM miR-155-3p: processing by-product or rising star in immunity and cancer? Open Biol [Internet]. 2022 [cited 2025 Aug 9];12(5):220070. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9131122\/","DOI":"10.1098\/rsob.220070"},{"key":"2774_CR14","doi-asserted-by":"crossref","unstructured":"Prieto I, Kavanagh M, Jimenez-Castilla L, Pardines M, Lazaro I, Herrero del Real I et al A mutual regulatory loop between miR-155 and SOCS1 influences renal inflammation and diabetic kidney disease. Mol Ther Nucleic Acids [Internet]. 2023 Dec 12 [cited 2025 Oct 4];34:102041. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10571033\/","DOI":"10.1016\/j.omtn.2023.102041"},{"key":"2774_CR15","doi-asserted-by":"crossref","unstructured":"Ren FJ, Yao Y, Cai XY, Fang GY Emerging Role of MiR-192-5p in Human Diseases. Front Pharmacol [Internet]. 2021 Feb 23 [cited 2025 Oct 4];12:614068. Available from: www.frontiersin.org","DOI":"10.3389\/fphar.2021.614068"},{"key":"2774_CR16","doi-asserted-by":"crossref","unstructured":"Ma L, Song H, Zhang CY, Hou D MiR-192-5p Ameliorates Hepatic Lipid Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting Yy1. Biomolecules [Internet]. 2024 Jan 1 [cited 2025 Oct 9];14(1):34. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10813355\/","DOI":"10.3390\/biom14010034"},{"key":"2774_CR17","doi-asserted-by":"crossref","unstructured":"Li S, Cheng F, Zhang Z, Xu R, Shi H, Yan Y The role of hepatocyte-derived extracellular vesicles in liver and extrahepatic diseases. Biomed Pharmacother [Internet]. 2024 Nov 1 [cited 2025 Oct 7];180:117502. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S075333222401388X","DOI":"10.1016\/j.biopha.2024.117502"},{"key":"2774_CR18","doi-asserted-by":"crossref","unstructured":"Liu XL, Pan Q, Cao HX, Xin FZ, Zhao ZH, Yang RX et al Lipotoxic Hepatocyte-Derived Exosomal MicroRNA 192-5p Activates Macrophages Through Rictor\/Akt\/Forkhead Box Transcription Factor O1 Signaling in Nonalcoholic Fatty Liver Disease. Hepatology [Internet]. 2020 Aug 1 [cited 2025 Oct 4];72(2):454\u201369. Available from:https:\/\/journals.lww.com\/hep\/fulltext\/2020\/08000\/lipotoxic_hepatocyte_derived_exosomal_microrna.10.aspx","DOI":"10.1002\/hep.31050"},{"key":"2774_CR19","doi-asserted-by":"crossref","unstructured":"Hwang S, Yang YM (2021) Exosomal microRNAs as diagnostic and therapeutic biomarkers in non-malignant liver diseases. Arch Pharm Res [Internet]. Jun 1 [cited 2025 Oct 7];44(6):574. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8223764\/","DOI":"10.1007\/s12272-021-01338-2"},{"key":"2774_CR20","doi-asserted-by":"crossref","unstructured":"Jain S, Thanage R, Panchal F, Rathi PM, Munshi R, Udgirkar SS et al Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link? J Clin Exp Hepatol [Internet]. 2020 Jul 1 [cited 2025 Aug 23];11(4):466. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8267349\/","DOI":"10.1016\/j.jceh.2020.10.003"},{"key":"2774_CR21","doi-asserted-by":"crossref","unstructured":"Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V et al Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest [Internet]. 2022 Nov 1 [cited 2025 Oct 9];132(21):e162513. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9621132\/","DOI":"10.1172\/JCI162513"},{"key":"2774_CR22","doi-asserted-by":"crossref","unstructured":"Huang DQ, Ahlholm N, Luukkonen PK, Porthan K, Amangurbanova M, Madamba E et al Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study. Clin Gastroenterol Hepatol [Internet]. 2024 Jan 1 [cited 2025 Oct 9];22(1):81\u201390.e4. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37406954\/","DOI":"10.1016\/j.cgh.2023.06.020"},{"key":"2774_CR23","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N et al The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol [Internet]. 2019 Oct 1 [cited 2025 Aug 23];71(4):793\u2013801. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827819303939","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"2774_CR24","doi-asserted-by":"crossref","unstructured":"Sumida Y, Yoneda M, Current and future pharmacological therapies for NAFLD\/NASH. J Gastroenterol [Internet]. 2018 Mar 1 [cited 2025 Aug 23];53(3):362\u201376. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29247356\/","DOI":"10.1007\/s00535-017-1415-1"},{"key":"2774_CR25","doi-asserted-by":"crossref","unstructured":"Huang YH, Chan C, Lee HW, Huang C, Chen YJ, Liu PC et al Influence of Nonalcoholic Fatty Liver Disease with Elevated Liver Enzyme Levels on Risk of Cirrhosis and Hepatocellular Carcinoma. Clin Gastroenterol Hepatol [Internet]. 2022 Apr 1 [cited 2025 Aug 23];21(4):960. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9349477\/","DOI":"10.1016\/j.cgh.2022.01.046"},{"key":"2774_CR26","doi-asserted-by":"crossref","unstructured":"Deprince A, Haas JT, Staels B (2020) Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab [Internet]. Dec 1 [cited 2025 Oct 9];42:101092. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7600388\/","DOI":"10.1016\/j.molmet.2020.101092"},{"key":"2774_CR27","doi-asserted-by":"crossref","unstructured":"Khalil F, Rafat MN, Salah M, Mohamed A, Ibrahim W (2018) Study of Lipid Profile in Different grades of Non-Alcoholic Fatty Liver Disease. Egypt J Hosp Med. ;73(8)","DOI":"10.21608\/ejhm.2018.18473"},{"key":"2774_CR28","doi-asserted-by":"crossref","unstructured":"Morsy Mohamed DA, Elmaleh DM, Abdel-wahed MA (2025) Impact of Vitamin D Deficiency on Diabetic Obese Patients with Non-Alcoholic Fatty Liver Disease. Cairo Univ [Internet]. [cited 2025 Aug 23];93(2). Available from: www.medicaljournalofcairouniversity.net","DOI":"10.21608\/mjcu.2025.444259"},{"key":"2774_CR29","doi-asserted-by":"crossref","unstructured":"Jung I, Koo DJ, Lee WY Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective. Diabetes Metab J [Internet]. 2024 May 1 [cited 2025 Aug 23];48(3):327. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11140401\/","DOI":"10.4093\/dmj.2023.0350"},{"key":"2774_CR30","doi-asserted-by":"publisher","unstructured":"Tian J, Cao Y, Zhang W, Wang A, Yang X, Dong Y et al The potential of insulin resistance indices to predict non-alcoholic fatty liver disease in patients with type 2 diabetes. BMC Endocr Disord [Internet]. 2024 Dec 1 [cited 2025 Aug 23];24(1):1\u201311. Available from: https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12902-024-01794-z","DOI":"10.1186\/s12902-024-01794-z"},{"key":"2774_CR31","doi-asserted-by":"crossref","unstructured":"Huang X, Sang Z, Liu H, Yang J, Wang K, Qu Y et al From nonalcoholic fatty liver disease to neuroinflammation: the role of chronic systemic inflammation. Metab Brain Dis [Internet]. 2025 Aug 1 [cited 2025 Aug 23];40(6):240. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12245968\/","DOI":"10.1007\/s11011-025-01669-9"},{"key":"2774_CR32","doi-asserted-by":"crossref","unstructured":"Kumar R, Porwal YC, Dev N, Kumar P, Chakravarthy S, Kumawat A (2020) Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study. J Fam Med Prim Care [Internet]. [cited 2025 Aug 23];9(1):390. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7014887\/","DOI":"10.4103\/jfmpc.jfmpc_887_19"},{"key":"2774_CR33","doi-asserted-by":"crossref","unstructured":"Shen M, Pan H, Ke J, Zhao F, NF-\u03baB-upregulated miR-155-5p promotes hepatocyte mitochondrial dysfunction to accelerate the development of nonalcoholic fatty liver disease through downregulation of STC1. J Biochem Mol Toxicol [Internet]. 2022 Jun 1 [cited 2025 Oct 9];36(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35603999\/","DOI":"10.1002\/jbt.23025"},{"key":"2774_CR34","doi-asserted-by":"crossref","unstructured":"Kan Changez MI, Mubeen M, Zehra M, Samnani I, Abdul Rasool A, Mohan A et al Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review. J Int Med Res [Internet]. 2023 Sep 1 [cited 2025 Oct 9];51(9):03000605231197058. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10492500\/","DOI":"10.1177\/03000605231197058"},{"key":"2774_CR35","doi-asserted-by":"crossref","unstructured":"Li H, Liu T, Yang Y, Cho WC, Flynn RJ, Harandi MF et al Interplays of liver fibrosis-associated microRNAs: Molecular mechanisms and implications in diagnosis and therapy. Genes Dis [Internet]. 2023 Jul 1 [cited 2025 Aug 23];10(4):1457\u201369. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352304222002343","DOI":"10.1016\/j.gendis.2022.08.013"},{"key":"2774_CR36","doi-asserted-by":"crossref","unstructured":"Ragab HM, Ezzat WM, Hassan EM, El Maksoud NA, Afify M, Abd El-Maksoud MDE et al Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease. J Genet Eng Biotechnol [Internet]. 2023 Dec 1 [cited 2025 Aug 23];21(1):13. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9911573\/","DOI":"10.1186\/s43141-023-00467-z"},{"key":"2774_CR37","doi-asserted-by":"publisher","unstructured":"Atic AI, Thiele M, Munk A, Dalgaard LT Circulating miRNAs associated with nonalcoholic fatty liver disease. Am J Physiol - Cell Physiol [Internet]. 2023 Feb 1 [cited 2024 Dec 14];324(2):C588\u2013602. Available from: https:\/\/doi.org\/10.1152\/ajpcell.00253.2022","DOI":"10.1152\/ajpcell.00253.2022"},{"key":"2774_CR38","doi-asserted-by":"crossref","unstructured":"Hochreuter MY, Dall M, Treebak JT, Barr\u00e8s R MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Mol Metab [Internet]. 2022 Nov 1 [cited 2025 Oct 9];65:101581. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9464960\/","DOI":"10.1016\/j.molmet.2022.101581"},{"key":"2774_CR39","doi-asserted-by":"publisher","unstructured":"Nogueira JP, Cusi K (2024) Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care. Diabetes Spectr [Internet]. Feb 15 [cited 2025 Feb 10];37(1):20\u20138. Available from: https:\/\/doi.org\/10.2337\/dsi23-0013","DOI":"10.2337\/dsi23-0013"},{"key":"2774_CR40","doi-asserted-by":"crossref","unstructured":"Fang Z, Dou G, Wang L (2021) MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Int J Biol Sci [Internet]. [cited 2025 Aug 23];17(7):1851. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8120467\/","DOI":"10.7150\/ijbs.59588"},{"key":"2774_CR41","doi-asserted-by":"crossref","unstructured":"Liu XL, Cao HX, Wang BC, Xin FZ, Zhang RN, Zhou D et al miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. World J Gastroenterol [Internet]. 2017 Dec 14 [cited 2025 Oct 9];23(46):8140. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5739921\/","DOI":"10.3748\/wjg.v23.i46.8140"},{"key":"2774_CR42","unstructured":"When adjusting for insulin resistance using HOMA-IR, the associations of both miRNAs with NAFLD lost significance and indicating that part of their effect is mediated through metabolic dysfunction, especially insulin resistance, which is a central driver of NAFLD progression: https:\/\/pubmed.ncbi.nlm.nih.gov\/39364176\/"},{"key":"2774_CR43","doi-asserted-by":"publisher","unstructured":"subgroups, while miR-192-5p remained significant only in NAFLD with T2DM. These findings suggest that miR-155p contributes independently to NAFLD risk, whereas miR-192-5p\u2019s effect may be context-dependent and influenced by vitamin D-modulated pathways: https:\/\/doi.org\/10.3390\/nu12113302","DOI":"10.3390\/nu12113302"},{"key":"2774_CR44","doi-asserted-by":"publisher","unstructured":"(Interestingly, adjusting for serum vitamin D levels revealed that miR-155-3p maintained a significant positive association across all subgroups, while miR-192-5p remained significant only in NAFLD with T2DM. These findings suggest that miR-155p contributes independently to NAFLD risk, whereas miR-192-5p\u2019s effect may be context-dependent and influenced by vitamin D-modulated pathways: https:\/\/doi.org\/10.3390\/biom14010034","DOI":"10.3390\/biom14010034"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02774-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02774-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02774-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:51:36Z","timestamp":1792641096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02774-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["2774"],"URL":"https:\/\/doi.org\/10.1007\/s00592-026-02774-6","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: due to affiliation 2 was incorrect in the article","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol was approved by the ethical guidelines of MUST University Ethics Committee (FWA00025577).","order":3,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}